Datapoint: Horizon Snags Gout Label Expansion for Krystexxa

The FDA on July 8 approved a label expansion for Horizon Therapeutics’ Krystexxa. The injectable, in combination with methotrexate, will be the first treatment available for uncontrolled gout in patients whose symptoms have not responded to other therapies. The drug was first approved in 2010. For the treatment of gouty arthritis, Krystexxa currently holds covered or better status for 57% of all insured lives under the pharmacy benefit. Krystexxa is not covered for 34% of lives.

Source: MMIT Analytics, as of 7/13/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today